Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Claris Life sciences is currently trading at Rs. 228.00, up by 3.45 points or 1.54% from its previous closing of Rs. 224.55 on the BSE.
The scrip opened at Rs. 226.60 and has touched a high and low of Rs. 228.85 and Rs. 224.00 respectively. So far 52876 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 292.20 on 05-Dec-2012 and a 52 week low of Rs. 98.10 on 19-Dec-2011.
Last one week high and low of the scrip stood at Rs. 266.90 and Rs. 216.00 respectively. The current market cap of the company is Rs. 1436.86 crore.
The promoters holding in the company stood at 62.06% while Institutions and Non-Institutions held 23.17% and 14.77% respectively.
Ahmedabad-based sterile injectables pharmaceutical firm, Claris Life sciences, is planning to invest Rs 900 crore, a part of divestment of 80 per cent stake in its infusion business, on various initiatives, including growth of business and pre-payment of debt.
Recently, the company divested 80 per cent stake in its infusion business for a total consideration of Rs 1,050 crore and has entered into a tripartite joint venture with two Japanese firms for the same. Drug firm executed agreements for a joint venture Claris-Otsuka; with Japan-based Otsuka Pharmaceutical Factory (OPF) and Mitsui & Co Ltd for its infusion business in India and emerging markets.
Further, besides earmarking Rs 900 crore for various initiatives, the company plans to utilize another Rs 300 crore for organic and inorganic growth of the speciality injectables business.
Ahmedabad based, Claris Lifesciences offers injectibles in various therapeutic segments including anesthesia, critical care, anti-infectives, renal care, infusion therapy, parenteral nutrition and oncology. It has presence in 91 countries across Latin America, Europe, Gulf, Africa, CIS, Central Asia and Asia- Pacific.
| Company Name | CMP |
|---|---|
| Adani Enterprises | 3115.75 |
| Redington | 212.30 |
| Amrapali Industries | 14.95 |
| Rashi Peripheral | 329.05 |
| Compuage Infocom | 4.15 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
